5.13
+0.06(+1.18%)
Currency In USD
| Previous Close | 5.07 |
| Open | 5.06 |
| Day High | 5.29 |
| Day Low | 4.97 |
| 52-Week High | 5.98 |
| 52-Week Low | 1.48 |
| Volume | 4.01M |
| Average Volume | 2.15M |
| Market Cap | 456.59M |
| PE | -6.41 |
| EPS | -0.8 |
| Moving Average 50 Days | 4.23 |
| Moving Average 200 Days | 3.43 |
| Change | 0.06 |
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetas
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewswire Inc.
Jun 04, 2025 12:00 PM GMT
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, J
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofi